Vertex Pharmaceuticals Inc

VRTX: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
^^xLOCK|TWz#LOCK|F^nNc%b

Narrow-Moat Vertex's Expanding Portfolio Strengthens Its Long-Term Outlook

Business Strategy and Outlook

Vertex Pharmaceuticals was known for discovering blockbuster hepatitis C drug Incivek, which is now overshadowed by the company's robust cystic fibrosis franchise. Vertex's approved cystic fibrosis drugs—Kalydeco, Orkambi, Symdeko, Trikafta, and Alyftrek—make the firm eligible to treat about 95% of the CF population. We expect Vertex to maintain its dominant position in CF, given the strong efficacy of its therapies, lengthy patents, and lack of competition, while developing pipeline candidates in other indications to spur growth.

Sponsor Center